• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    General Counsel Smith Jason Drew sold $19,895 worth of Ordinary Shares (1,521 units at $13.08) and converted options into 3,333 units of Ordinary Shares, increasing direct ownership by 8% to 25,226 units (SEC Form 4)

    9/12/24 1:51:58 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $URGN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Smith Jason Drew

    (Last) (First) (Middle)
    400 ALEXANDER PARK DRIVE

    (Street)
    PRINCETON NJ 08540

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    UroGen Pharma Ltd. [ URGN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    General Counsel
    3. Date of Earliest Transaction (Month/Day/Year)
    09/09/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares 09/09/2024 M 3,333 A (1) 26,747 D
    Ordinary Shares 09/09/2024 S 1,521(2) D $13.08 25,226 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 09/09/2024 M 3,333 (3) (3) Ordinary Shares 3,333 $0 6,667 D
    Explanation of Responses:
    1. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
    2. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
    3. The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.
    /s/ Jason D. Smith, Attorney-in-Fact 09/12/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $URGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $URGN

    DatePrice TargetRatingAnalyst
    6/16/2025$50.00Neutral → Buy
    H.C. Wainwright
    5/22/2025Buy → Neutral
    H.C. Wainwright
    4/16/2025$23.00Sector Outperform
    Scotiabank
    2/19/2025$31.00Buy
    Ladenburg Thalmann
    8/22/2024$40.00Buy
    Guggenheim
    2/8/2023$35.00 → $10.00Buy → Hold
    Jefferies
    4/27/2022$20.00Buy
    Berenberg
    1/18/2022$50.00 → $34.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $URGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Barrett Elizabeth A.

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      7/30/25 4:08:22 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Smith Jason Drew sold $143,971 worth of Ordinary Shares (7,522 units at $19.14) and converted options into 16,500 units of Ordinary Shares, increasing direct ownership by 28% to 41,492 units (SEC Form 4)

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      7/30/25 4:03:45 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Schoenberg Mark converted options into 10,000 units of Ordinary Shares and sold $98,552 worth of Ordinary Shares (5,149 units at $19.14), increasing direct ownership by 3% to 158,229 units (SEC Form 4)

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      7/30/25 4:02:05 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $URGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

      Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2025 financial results on Thursday, August 7th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay wil

      7/29/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

      PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, today announced the publication in Reviews in Urology of results from a Phase 3b study evaluating the feasibility of administering ZUSDURI™ (mitomycin) for intravesical solution (formerly known as UGN-102) in the home setting. The study, titled "Home Instillation of UGN-102 for Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Single-Arm, Open-Label, Phase 3b Trial," demonstrated that trained home health professionals (HHPs) can safely

      7/28/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

      Findings published in the journal of Clinical Genitourinary Cancer show patients remained event-free for a median of two years after achieving complete response with ZUSDURI (mitomycin) intravesical solution. Among the 17 patients who achieved complete response and entered a long-term extension study, the median duration of response was 3.5 years by Kaplan-Meier estimate. PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions for urothelial and specialty cancers, today announced the publication of results of a five-year long-term extension study of the Phase 2b OPTIMA II trial

      7/21/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $URGN
    SEC Filings

    See more
    • SEC Form DEF 14A filed by UroGen Pharma Ltd.

      DEF 14A - UroGen Pharma Ltd. (0001668243) (Filer)

      7/15/25 4:56:18 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by UroGen Pharma Ltd.

      8-K - UroGen Pharma Ltd. (0001668243) (Filer)

      7/3/25 4:16:10 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by UroGen Pharma Ltd.

      8-K - UroGen Pharma Ltd. (0001668243) (Filer)

      6/13/25 8:00:29 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $URGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UroGen Pharma upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded UroGen Pharma from Neutral to Buy and set a new price target of $50.00

      6/16/25 7:44:13 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma downgraded by H.C. Wainwright

      H.C. Wainwright downgraded UroGen Pharma from Buy to Neutral

      5/22/25 8:22:21 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on UroGen Pharma with a new price target

      Scotiabank initiated coverage of UroGen Pharma with a rating of Sector Outperform and set a new price target of $23.00

      4/16/25 8:14:26 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $URGN
    Financials

    Live finance-specific insights

    See more
    • UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

      Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2025 financial results on Thursday, August 7th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay wil

      7/29/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

      ZUSDURI (formerly known as UGN-102) is a localized medication designed for potent tumor ablation delivered by innovative RTGel® technology. Approval supported by pivotal Phase 3 ENVISION trial demonstrating 78% of patients achieved complete response (CR) at 3 months, and 79% of those responders maintained complete response at 12 months after the 3-month visit (DOR). Manageable safety profile characterized primarily by mild to moderate lower urinary tract symptoms. An estimated 59,000 LG-IR-NMIBC patients in the U.S. recur each year and face repeat surgeries. Conference call and webcast to be held on June 13, 2025, at 8:30 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech com

      6/12/25 1:28:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update

      New Drug Application for UGN-102 on track for FDA-PDUFA target action date of June 13, 2025; assuming approval, commercial launch to immediately follow with product availability in July Oncologic Drugs Advisory Committee scheduled for May 21, 2025 JELMYTO® achieved net product sales of $20.3 million in Q1 2025, compared with $18.8 million in Q1 2024, driven by underlying demand growth of 12% $200.4 million in cash, cash equivalents and marketable securities as of March 31, 2025 Conference call and webcast to be held today at 10:00 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and sp

      5/12/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $URGN
    Leadership Updates

    Live Leadership Updates

    See more
    • UroGen Appoints Chris Degnan as Chief Financial Officer

      Mr. Degnan has extensive experience in financial strategy, investor relations, SEC reporting, accounting and compliance UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has been appointed Chief Financial Officer. Mr. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities. "Under Don's financial stewardship, we have strengthened our financial position and achieved significant milestones, which include multiple capital raises and investing in the potential commercial launch of UGN-102 for low-grade intermediate-risk non-musc

      10/9/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Appoints David Lin as New Chief Commercial Officer

      UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team. In this role, David will be spearheading UroGen's commercial strategy, including preparation for the potential launch of our lead pipeline candidate UGN-102, if approved, and driving the continued growth and commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution. David Lin brings to UroGen a wealth of experience garnered from a distinguished career in the pharmaceutical industry. Prior to joining U

      6/3/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $URGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by UroGen Pharma Ltd.

      SC 13D/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/18/24 6:16:04 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

      SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/14/24 7:46:37 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

      SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/14/24 5:46:12 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care